Findings support early adjunctive COMT inhibition as a safe, translatable symptomatic strategy that may delay motor complications, making it relevant for clinical management and pragmatic therapeutic optimization even though it does not demonstrate disease modification.

These validated patient-specific iPSC lines provide a relevant human cellular platform to study GBA1-linked lysosomal dysfunction and alpha-synuclein mechanisms and to support target validation and screening of GBA1- or lysosome-directed therapeutics.

By defining and detecting specific alpha-synuclein aggregate subtypes with highly sensitive methods, this work provides tools and candidate biomarkers to improve target engagement assays, stratify pathology-relevant species, and inform timing/targets for therapies directed at aggregate clearance or…

As a non-invasive, quantitative biomarker for differential diagnosis and motor monitoring in parkinsonian syndromes, this method can improve patient selection and outcome measurement in trials, though it does not directly reveal PD therapeutic targets or mechanisms.

Offers promising diagnostic biomarkers and a transparent classification tool that could improve early detection and patient stratification for clinical studies, but provides limited direct mechanistic or therapeutic target information for drug discovery.

Offers a noninvasive, data-driven gait biomarker and analytic pipeline that could help monitor and stratify patient treatment responses in PD, but provides little mechanistic or therapeutic target information for drug discovery.

By enabling gold-standard correlation of longitudinal clinical, imaging, genetic, and biofluid biomarkers with neuropathology, this resource strengthens biomarker validation and translational readiness, indirectly supporting Parkinson's therapeutic discovery and trial development.

Although not a mechanistic or therapeutic study, this objective, low-cost biomarker method could improve monitoring, remote assessment, dose titration, and trial outcome measurement for dyskinesia, thereby aiding translational and clinical decision-making.

The device offers an accessible, real‑time tremor monitoring and diagnostic tool that can aid patient stratification and remote data collection for clinical studies, but it provides minimal insight into PD pathophysiology or direct therapeutic targets.

Although it lacks molecular or intervention insights, the study offers potentially useful cross-disease neuroimaging biomarkers for early detection and cohort stratification that could improve Parkinson's trial design and biomarker-driven therapeutic development.

This work offers a scalable, accessible diagnostic/screening tool that could aid early detection, monitoring, and patient stratification for clinical studies, but it provides little direct insight into mechanisms or therapeutic targets for Parkinson's disease.

The work has limited direct therapeutic discovery value—no mechanistic targets or interventions—but the multimodal diagnostic method could help early detection and patient stratification for Parkinson's clinical studies if rigorously validated on diverse cohorts.

The findings highlight geographic disparities in diagnosis, treatment access, and comorbidity management relevant for public-health planning and trial site selection, but provide limited actionable insight for molecular targets or therapeutic development.

Direct therapeutic-discovery value is low, but the findings matter for clinical translation and research conduct because clinicians and trialists must address and validate patient-sourced AI outputs to preserve shared decision-making, data quality, and safety.

Improves diagnostic accuracy and early detection workflows, but provides no mechanistic, biomarker, or therapeutic insights relevant to drug discovery, limiting its translational value for PD therapeutics.

The results are useful for healthcare planning and for designing clinical studies or care models by highlighting acute-care burden and persistent supportive-care needs, but the paper provides little mechanistic or therapeutic-discovery insight for Parkinson’s drug development.

It is relevant to Parkinson's research because it links immune-mediated BBB dysfunction and HLA-associated susceptibility to mechanisms that could yield immune-targeted therapies or biomarkers, though its broad, review-style treatment offers limited PD-specific actionable targets.

Provides proof-of-concept that non‑invasive, anatomically individualized temporal interference neuromodulation can acutely improve Parkinsonian motor symptoms and could be developed as a less invasive alternative to STN‑DBS, meriting larger trials to test durability, dosing, and specificity.

The multi-omics, colocalized genetic evidence prioritizes AMIGO1 as a genetically supported candidate for mechanistic follow-up and potential biomarker or therapeutic development in PD, though functional validation is still required.

Although not directly therapeutic, the model links DA/NA and STN population dynamics to decision-making deficits in Parkinson's disease, offering a mechanistic computational platform to generate testable hypotheses for neuromodulation strategies or noradrenergic-focused interventions.